SAFETY, PHARMACOKINETICS, AND ACTIVITY OF THE ANTI-NAPI2B ANTIBODY-DRUG CONJUGATE DNIB0600A: A PHASE I STUDY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND PLATINUM-RESISTANT OVARIAN CANCER

被引：0

作者：

Gerber, David ^{[1
]}

Infante, Jeffrey ^{[2
]}

Gordon, Michael ^{[3
]}

Schiller, Joan ^{[1
]}

Spigel, David ^{[4
]}

Wang, Yulei ^{[5
]}

Shames, David S. ^{[5
]}

Choi, Younjeong ^{[5
]}

Kahn, Robb ^{[5
]}

Xu, Jian ^{[5
]}

Lin, Kedan ^{[5
]}

Wood, Katie ^{[5
]}

Maslyar, Daniel ^{[5
]}

Burris, Howard ^{[4
]}

机构：

[1] UT Southwestern Med Ctr, Harold C Simmons Canc Ctr, Dallas, TX USA

[2] Tennessee Oncol Pllc, Sarah Cannon Res Inst, Nashville, TN USA

[3] Pinnacle Oncol Hematol, Scottsdale, AZ USA

[4] Sarah Cannon Res Inst, Nashville, TN USA

[5] Genentech Inc, San Francisco, CA USA

来源：

关键词：

NSCLC; ADC; Phase I; NaPi2b;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.11-014

引用

页码：S1190 / S1191

页数：2

共 22 条